The
global Non-Invasive Prenatal Testing Market is
anticipated to reach USD 5.5 billion by 2025, according to a new report by
Grand View Research, Inc. Evolution of prenatal testing in the form of
noninvasive tests that can serve as an intermediate step between serum
screening and invasive diagnostic testing to determine the likelihood of fetal
abnormality is expected to drive growth in the reproductive genetics industry
over the forecast period.
Further Key Findings fromthe Report Suggest:
In
addition, presence of payers such as Anthem and Blue Shield of California that
have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13,
18, and 21 is expected to impact the adoption rate of these tests, thereby
resulting in increased revenue generation.
However,
the projected NIPT-related price erosion in this market is expected to
continue, thus intensifying competition amongst the operating participants, but
restraining revenue generation to a certain extent.
Browse
Details of Report @
http://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market
http://www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market
Further Key Findings fromthe Report Suggest:
- The market is segmented on
the basis of the tests carried out during the gestation period as 0-12
weeks, 13-24 weeks, and 25-36 weeks
- 13-24 weeks accounted for
the largest share owing to the presence of maximum number of the tests
carried out in this phase of pregnancy
- High & average risk
pregnancy held the larger share owing to presence of favorable payer
reimbursement in this segment
- Rising awareness
pertaining to the prevention and screening of chromosomal anomalies, such
as Down Syndrome is another factor anticipated to impact adoption
- Asia Pacific is expected
to register fastest year-on-year progress owing to the gradually
increasing average maternal age, & increasing incidence of chromosomal
aneuploidies
- Some of the key players
operating the market space include Natera, Inc;Illumina, Inc; Sequenom;
Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp
- One of the key trends
followed by companies includes licensing of the test to other labs and
generating significant revenue by collecting royalty payments
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment